KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash & Equivalents (2016 - 2025)

Abbott Laboratories' Cash & Equivalents history spans 17 years, with the latest figure at $8.5 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 11.9% year-over-year to $8.5 billion; the TTM value through Dec 2025 reached $8.5 billion, up 11.9%, while the annual FY2025 figure was $8.5 billion, 11.9% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $8.5 billion at Abbott Laboratories, up from $7.5 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $9.9 billion in Q4 2022 and bottomed at $6.3 billion in Q1 2024.
  • The 5-year median for Cash & Equivalents is $7.8 billion (2022), against an average of $8.0 billion.
  • The largest annual shift saw Cash & Equivalents surged 138.5% in 2021 before it tumbled 31.4% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $9.8 billion in 2021, then increased by 0.85% to $9.9 billion in 2022, then crashed by 30.22% to $6.9 billion in 2023, then grew by 10.44% to $7.6 billion in 2024, then grew by 11.9% to $8.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Cash & Equivalents are $8.5 billion (Q4 2025), $7.5 billion (Q3 2025), and $7.0 billion (Q2 2025).